BR112023023092A2 - Promotores de células de suporte vestibular e usos dos mesmos - Google Patents
Promotores de células de suporte vestibular e usos dos mesmosInfo
- Publication number
- BR112023023092A2 BR112023023092A2 BR112023023092A BR112023023092A BR112023023092A2 BR 112023023092 A2 BR112023023092 A2 BR 112023023092A2 BR 112023023092 A BR112023023092 A BR 112023023092A BR 112023023092 A BR112023023092 A BR 112023023092A BR 112023023092 A2 BR112023023092 A2 BR 112023023092A2
- Authority
- BR
- Brazil
- Prior art keywords
- transgene
- vestibular
- support cell
- cell promoters
- promoters
- Prior art date
Links
- 230000001720 vestibular Effects 0.000 title abstract 5
- 108700019146 Transgenes Proteins 0.000 abstract 5
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184015P | 2021-05-04 | 2021-05-04 | |
| PCT/US2022/027679 WO2022235805A1 (en) | 2021-05-04 | 2022-05-04 | Vestibular supporting cell promoters and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023092A2 true BR112023023092A2 (pt) | 2024-01-30 |
Family
ID=83932529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023092A BR112023023092A2 (pt) | 2021-05-04 | 2022-05-04 | Promotores de células de suporte vestibular e usos dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240218391A1 (https=) |
| EP (1) | EP4334460A4 (https=) |
| JP (1) | JP2024517250A (https=) |
| KR (1) | KR20240031224A (https=) |
| CN (1) | CN117616127A (https=) |
| AU (1) | AU2022271238A1 (https=) |
| BR (1) | BR112023023092A2 (https=) |
| CA (1) | CA3219057A1 (https=) |
| CL (2) | CL2023003257A1 (https=) |
| CO (1) | CO2023016746A2 (https=) |
| IL (1) | IL308143A (https=) |
| MX (1) | MX2023013058A (https=) |
| WO (1) | WO2022235805A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140024663A1 (en) * | 2012-07-17 | 2014-01-23 | Georgia Health Sciences University Research Institute, Inc. | Atb(0,+) amino acid transporter as a drug target for treatment of estrogen receptor-positive breast cancer |
| US20160298080A1 (en) * | 2013-12-03 | 2016-10-13 | The Johns Hopkins University | Method for highly efficient conversion of human stem cells to lineage-specific neurons |
| SG10201913266UA (en) * | 2015-12-11 | 2020-02-27 | Massachusetts Eye & Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
-
2022
- 2022-05-04 AU AU2022271238A patent/AU2022271238A1/en active Pending
- 2022-05-04 MX MX2023013058A patent/MX2023013058A/es unknown
- 2022-05-04 EP EP22799511.5A patent/EP4334460A4/en active Pending
- 2022-05-04 KR KR1020237041741A patent/KR20240031224A/ko active Pending
- 2022-05-04 WO PCT/US2022/027679 patent/WO2022235805A1/en not_active Ceased
- 2022-05-04 US US18/289,031 patent/US20240218391A1/en active Pending
- 2022-05-04 CA CA3219057A patent/CA3219057A1/en active Pending
- 2022-05-04 IL IL308143A patent/IL308143A/en unknown
- 2022-05-04 JP JP2023568110A patent/JP2024517250A/ja active Pending
- 2022-05-04 BR BR112023023092A patent/BR112023023092A2/pt unknown
- 2022-05-04 CN CN202280036423.1A patent/CN117616127A/zh active Pending
-
2023
- 2023-11-02 CL CL2023003257A patent/CL2023003257A1/es unknown
- 2023-12-01 CO CONC2023/0016746A patent/CO2023016746A2/es unknown
-
2024
- 2024-08-29 CL CL2024002594A patent/CL2024002594A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022271238A9 (en) | 2024-01-04 |
| CN117616127A (zh) | 2024-02-27 |
| WO2022235805A1 (en) | 2022-11-10 |
| IL308143A (en) | 2023-12-01 |
| CO2023016746A2 (es) | 2024-02-26 |
| MX2023013058A (es) | 2023-12-14 |
| CL2024002594A1 (es) | 2025-01-03 |
| EP4334460A1 (en) | 2024-03-13 |
| AU2022271238A1 (en) | 2023-12-14 |
| KR20240031224A (ko) | 2024-03-07 |
| EP4334460A4 (en) | 2025-11-05 |
| US20240218391A1 (en) | 2024-07-04 |
| JP2024517250A (ja) | 2024-04-19 |
| CA3219057A1 (en) | 2022-11-10 |
| CL2023003257A1 (es) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| BR112022016550A2 (pt) | Proteínas de ligação a flt3 e métodos de uso | |
| MX2018001040A (es) | Moleculas de acido nucleico artificiales. | |
| BR112021010354A2 (pt) | Métodos para o tratamento usando terapia celular adotiva | |
| BRPI0508424A (pt) | muteìnas de interleucina-2 melhoradas | |
| BR112018075688A2 (pt) | anticorpos anti-c5 e métodos de uso | |
| MX2016008551A (es) | Moleculas artificiales de acido nucleico. | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| BR112012025730A2 (pt) | "anticorpos anti-erbb3, seus usos e seu processo de produção, ácidos nucleicos, vetores de expressão, células hospedeiras, bem como processo de produção de um polipeptídeo" | |
| BR112015019729A2 (pt) | composição inibidora da il-1b e uso da mesma | |
| BR112023002724A2 (pt) | Neoantígenos ras e seus usos | |
| BR112021019109A2 (pt) | Célula rpe manipulada, composições, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método para aplicar uma terapia com fvii | |
| BR112022025019A2 (pt) | Fusões heterodiméricas de relaxina e usos das mesmas | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| BR112021017464A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112023022833A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de estereocilina | |
| CO2023000307A2 (es) | Polipéptidos de mybpc3 y usos de los mismos | |
| BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
| MX2021000322A (es) | Enzimas de variante fosfopentomutasa modificada geneticamente. | |
| BR112021017479A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112022006923A2 (pt) | Polipeptídeos recombinantes para localização celular regulável | |
| BR112023004871A2 (pt) | Métodos para reduzir o conteúdo de proteínas das células hospedeiras em processos de purificação de proteínas | |
| BR112016014072A8 (pt) | anticorpo isolado, sintético ou recombinante humano, ou uma parte funcional ou um equivalente funcional do mesmo, molécula de ácido nucleico isolado, sintético ou recombinante, vetor, célula isolada ou recombinante ou um animal não humano, composição, uso de um anticorpo ou parte funcional ou equivalente funcional, e, métodos para produzir um anticorpo ou parte funcional ou equivalente funcional, para detectar células mieloproliferativas ou linfoproliferativas, para determinar se uma célula mieloide ou célula linfoide é uma célula mieloproliferativa ou célula linfoproliferativa, para identificar células mieloproliferativas ou linfoproliferativas, para determinar se células mieloproliferativas ou linfoproliferativas estão presentes em uma amostra, para tratar e/ou prevenir um distúrbio mieloproliferativo ou linfoproliferativo, para determinar se um indivíduo sofre de um distúrbio mieloproliferativo ou linfoproliferativo, para tipificar uma amostra contendo célula mieloide ou uma amostra contendo célula linfoide de um indivíduo, e, para determinar se um paciente que sofre de um distúrbio mieloproliferativo ou distúrbio linfoproliferativo é um candidato para o tratamento com um anticorpo |